mereo is a new uk-based speciality biopharmaceutical company focussed on the acquisition and rapid development of innovative medicines that have the potential to transform patient quality of life and improve human health. mereo intends to optimise the commercial value of programmes by entering into partnering deals at key value inflection points or, for selected opportunities, commercialising products itself. mereo is building a strong pipeline of innovative medicines, particularly focused in rare and specialist disease areas, through the acquisition of validated, mid-stage development programmes from large biopharmaceutical companies. mereo has access to an extensive network of experts with experience across multiple clinical disciplines for the clinical development of its portfolio.
Company profile
Ticker
MREO
Exchange
Website
CEO
Denise Pollard-Knight
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Mereo Biopharma Group plc
SEC CIK
MREO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27 Mar 24
S-8
Registration of securities for employees
23 Jan 24
8-K
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
8 Jan 24
8-A12B/A
Registration of securities on exchange (amended)
18 Dec 23
6-K
Current report (foreign)
18 Dec 23
6-K
Current report (foreign)
29 Nov 23
Latest ownership filings
SC 13D/A
Rubric Capital Management LP
16 Apr 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G
MANGROVE PARTNERS IM, LLC
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
4
Anders Ekblom
9 Feb 24
4
Pierre Jacquet
9 Feb 24
4
Marc J Yoskowitz
9 Feb 24
4
DEEPIKA PAKIANATHAN
9 Feb 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 59 |
Opened positions | 13 |
Closed positions | 7 |
Increased positions | 12 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 88.24 bn |
Total shares | 119.14 mm |
Total puts | 13.80 k |
Total calls | 106.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Soleus Private Equity Fund III | 30.24 mm | $36.90 mm |
Baker Bros. Advisors | 14.60 mm | $19.42 mm |
Rubric Capital Management | 11.62 mm | $14.98 bn |
Soleus Capital Management | 9.68 mm | $12.48 bn |
Rock Springs Capital Management | 7.68 mm | $9.90 bn |
Suvretta Capital Management | 7.36 mm | $9.50 bn |
683 Capital Management | 6.00 mm | $7.74 bn |
Mangrove Partners | 5.53 mm | $7.14 bn |
Vivo Capital IX | 3.76 mm | $0.00 |
Alkeon Capital Management | 3.74 mm | $4.82 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Feb 24 | Anders Ekblom | RSU American Depository Shares | Grant | Acquire A | No | No | 0 | 19,471 | 0.00 | 19,471 |
8 Feb 24 | Anders Ekblom | Share Options American Depository Shares | Grant | Acquire A | No | No | 3.87 | 45,000 | 174.15 k | 45,000 |
8 Feb 24 | Jacquet Pierre | RSU American Depository Shares | Grant | Acquire A | No | No | 0 | 15,553 | 0.00 | 15,553 |
8 Feb 24 | Jacquet Pierre | Share Options American Depository Shares | Grant | Acquire A | No | No | 3.87 | 45,000 | 174.15 k | 45,000 |
8 Feb 24 | Marc J Yoskowitz | RSU American Depository Shares | Grant | Acquire A | No | No | 0 | 14,139 | 0.00 | 14,139 |
8 Feb 24 | Marc J Yoskowitz | Share Options American Depository Shares | Grant | Acquire A | No | No | 3.87 | 45,000 | 174.15 k | 45,000 |
8 Feb 24 | Pakianathan Deepika | Share Options American Depository Shares | Grant | Acquire A | No | No | 3.87 | 45,000 | 174.15 k | 45,000 |
8 Feb 24 | Wyzga Michael S | RSU American Depository Shares | Grant | Acquire A | No | No | 0 | 30,783 | 0.00 | 30,783 |
8 Feb 24 | Wyzga Michael S | Share Options American Depository Shares | Grant | Acquire A | No | No | 3.87 | 45,000 | 174.15 k | 45,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Apr 24
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
10 Apr 24
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
28 Mar 24
Needham Maintains Buy on Mereo BioPharma Group, Raises Price Target to $6
28 Mar 24
Mereo BioPharma Group FY EPS $(0.04) Up From $(0.07) YoY, Sales $10.00M
27 Mar 24
Press releases
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
3 Apr 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27 Mar 24
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
5 Mar 24